** Shares of LAVA Therapeutics LVTX.O rise 27.4% to $1.20 premarket, after drug developer says it is evaluating strategic options, including a potential sale or merger
** Co says it will continue to enroll patients in the early-stage clinical study of LAVA-1266 for treating hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndrome
** Co also has implemented a restructuring plan, which includes a workforce reduction of about 30% to reduce costs and conserve cash
** As of Dec 31, 2023, co had 35 full-time employees - SEC filing
** Co estimates it will incur $500,000 in one-time costs related to the workforce reduction in Q1 2025
** LVTX had $76.6 mln in cash as of Dec 31, 2024
** LVTX fell 45.7% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。